Total protein brain homogenates were separated on SDS-PAGE gels, and blots were analyzed with three anti-α-synuclein antibodies (Syn204, LB509, and SNL1). SNL1 detects both murine and human α-synuclein; Syn204 selectively recognizes human α-synuclein; and LB509 is specific for human α-synuclein. Immunoblotting for actin was used as a loading control. (C) Double-label immunofluorescence staining of white matter of the spinal cord in 18-month-old M2 (C1-C3) and age-matched nontransgenic (C4-C6) mice. CNP colocalizes with α-synuclein (SNL1) in the cytoplasm of the oligodendrocytes in M2 mice (arrows). Scale bar, 15 m. (D) In situ hybridization was used to assess the expression of α-synuclein mRNA in 12-month-old M2 and age-matched non-Tg mice. Micrographs of emulsion-dipped in situ hybridization with two probes specific for human α-synuclein mRNA show that human α-synuclein is expressed only in oligodendrocytes (arrowheads), but not in neurons (arrows) (D1 and D2). In contrast, the in situ hybridization using a probe specific for mouse endogenous α-synuclein mRNA reveals that mouse α-synuclein is expressed in neurons (arrows), but not in oligodendrocytes (arrowheads), in the M2 Tg (D3) and in non-Tg control mice (D4). Scale bar, 6 m. (E) Immunohistochemical analysis of cerebral cortex (cerebrum) and spinal cord in 3-month-old M2 (E1 and E4) and 18-month-old M2 Tg mice (E2 and E5), and age-matched controls (E3 and E6). SNL1 staining shows the typical neuropil distribution of α-synuclein in addition to α-synuclein expression in oligodendrocytes of M2 Tg mice, but not in oligodendrocytes of non-Tg mice. No pathological change is observed in the neuropil of M2 Tg mice at 3 months, but accumulations of α-synuclein are detected in the neuropil at 18 months. Scale bar, 15 m. overexpression in oligodendrocytes was relatively low, vealed a decrease in the endurance time for motor performance beginning at 7-9 months of age ( Figure 2A ). since the levels of total α-synuclein (both human and However, the weekly rotarod test in mice examined endogenous mouse) expression as detected by SNL1 from 6 weeks to 32 weeks showed no significant differdid not differ significantly between non-Tg and the M2 ence between M2 and non-Tg mice (data not shown), Tg line ( Figure 1B ). Northern analysis of Tg human and consistent with an age-related rather than a developendogenous mouse α-synuclein mRNA in M2 and nonmental motor abnormality in M2 mice. To assess pure Tg mouse brain indicated that the levels of human muscle strength of mouse forepaws, the mice were ex-α-synuclein mRNA were much less than those of enamined in a wire hanging test. This test confirmed a dogenous mouse α-synuclein in M2 Tg mice (Figure progressive reduction in grip strength of M2 mice with S1). Nevertheless, we observed an age-dependent advancing age ( Figure 2B ), and this was associated increase in human α-synuclein in total brain homogewith progressive brain atrophy ( Figure 3A ). Quantitative nates from the M2 mice, suggesting an accumulation of analysis of brain weight in M2 (n = 5) and control non-α-synuclein protein in oligodendrocytes as the animals Tg (n = 5) mice demonstrated a 16% reduction at 24 aged. To demonstrate that the cells expressing human months of age (p < 0.01) and an 8.8% decrease at 9 α-synuclein were indeed oligodendrocytes in M2 mice, months of age (p < 0.01) in M2 mice ( Figure 3B ). There double-label immunofluorescence staining was conwas no significant change in brain weight between M2 ducted with anti-α-synuclein and anti-CNP (a marker and non-Tg mice at 1 and 3 months of age, thereby of oligodendrocytes) antibodies. The colocalization of indicating no developmental abnormality in M2 mice. human α-synuclein with CNP confirmed that oligoThe brain atrophy reflected a reduction in the neuropil dendrocytes are the only cells that express human and white matter, which most likely resulted from cell α-synuclein ( Figure 1C) . In situ hybridization with two loss in M2 mice ( Figure 3C ). Despite this reduction in human α-synuclein-specific probes revealed the selecbrain size, the life span of M2 mice was not affected tive presence of human α-synuclein mRNA in oligodencompared with non-Tg mice. At the age of 24 months, drocytes but not in neurons of M2 mice ( Figure 1D ). The the survival rate was 89% in M2 mice (n = 36) and 83% distribution of human α-synuclein in oligodendrocytes in control non-Tg mice (n = 30). The longest survival was analyzed next by immunohistochemistry in brain span was 33 months in M2 mice and 34 months in conand spinal cord of 3-, 10-, 18-, and 24-month-old M2 trols. mice, and we demonstrated that α-synuclein also accuTo assess if the motor impairments are associated mulated in the neuropil with increasing age ( Figure 1E2 with oligodendrocytic and/or neuronal degeneration in and 1E5). M2 mice, quantitative analyses of oligodendrocytes and neurons in the spinal cord were performed in 24-CNP-␣-Synuclein M2 Mice Develop Age-Related month-old M2 Tg and age-matched non-Tg control Motor Impairments and Neurodegeneration mice. These analyses showed a decrease in the numTo assess if the expression and progressive accumulaber of oligodendrocytes and neurons in the M2 mice tion of human α-synuclein in oligodendrocytes give rise compared to the non-Tg mice ( Figure 3E ). In particular, to a clinical phenotype, we examined the motor funcneuronal loss was most prominent in the lateral and tion of M2 mice. Tg mice did not exhibit any motor immedial columns of M2 mice ( Figure 3D ). Quantitative pairment on a flat surface except for slow motor activity analyses of dopaminergic neurons, however, showed when compared with non-Tg mice. However, when M2 no decrease in M2 mice (data not shown). mice were subjected to other motor testing paradigms, they showed several distinct motor impairments when Pathological Changes in the CNS of M2 Mice compared with age-matched non-Tg mice (Figures 2A
Since human α-synuclein accumulates in oligodendrocytes as GCIs in an age-dependent manner during MSA and 2B). For example, the rotarod treadmill test re- and 7C ), the tubular structures in the axon-terminal inin diameter, was identified in the spinal cord of M2 mice using transmission EM (Figures 6F and 6I) . Since the clusions were not decorated by LB509 but instead only reacted with the antibodies that recognized both ensame appearance of disordered tubular structures was observed in the degenerating axon terminals in the spidogenous mouse and human α-synucleins (SNL1) (Figure 7O ). nal cord (Figures 6G and 6H) , these pathological inclusions may be derived from degenerating axon terminals.
That mouse α-synuclein accumulated in axons and nerve terminals of M2 mice was further confirmed by The degenerating axon terminals, which showed accumulations of α-synuclein ( Figures 7I and 7L 
(K) Higher magnification of the boxed area in the axon in (J) demonstrates that SNL1 detects individual fibrils, approximately 10-15 nm in diameter (arrowheads). (L) Higher magnification view of the degenerating axon terminal in the boxed area in (I) shows that the terminal is enlarged by accumulation of α-synuclein fibrils (arrowheads) and disordered tubular structures with mitochondria (m). (M) An abnormal inclusion in axon terminal in the spinal cord of a 24-month-old M2 mouse is stained with SNL1. (N) Middle magnification of the inclusion (M) shows that the inclusion is mostly composed by disordered tubules. (O) In high magnification of the inclusion (M), the inclusion contains 25-35 nm tubules that are immunolabeled with SNL1 (arrowheads). Scale bars, 2 m (A, F, G, and M); 500 nm (B, D, E, H-L, and N); and 100 nm (C and O).
In sharp contrast, 7544 detected mouse α-synuclein in inclusions that we observed here in the degenerating axon terminals as well as within the axons of M2 mice axons and in axonal terminals around spinal cord motor neurons in M2 Tg mice. These accumulations of mouse were comprised of endogenous mouse α-synuclein. α-synuclein in the spinal cord of M2 mice are specific, since anti-synaptophysin antibodies did not immunoDiscussion stain these aberrant nerve terminals but weakly stained the degenerating axons (data not shown). Furthermore, We have demonstrated here that the M2 Tg mice expressing human α-synuclein in oligodendrocytes exincreased mouse α-synuclein at synaptic terminals in the hippocampus of M2 mice was detected by SNL1 hibited a primary oligodendrocytic as well as a secondary neuronal degenerative phenotype with motor when compared with non-Tg mice (Figures 8C and 8D We observed significant oligodendroglia and neuron loss in spinal cord and cortical areas in the M2 mice, and the distribution of neuronal loss in the spinal cord showed similarity to human MSA pathology (Papp and Lantos, 1994). The lack of overt degeneration in cerebellum and the pontine nuclei may be due to the lower levels of α-synuclein expression, since our biochemical analyses showed much lower levels of α-synuclein in cerebellum than in cortex and spinal cord. We also observed significant demyelination in the M2 mice. Although pronounced demyelination in MSA was not ob- terized by autophagocytosis in the oligodendrocytes and unique structural inclusions in the axon terminals.
Motor Testing
Although oligodendrocytes are known to form myelin 
